MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Orphan Drug Designation granted in the US by the FDA ("US Food and Drug Administration") for laquinimod for the treatment of Huntington's disease
ANYARA
- A licensing agreement has been entered into with NeoTX Therapeutics Ltd
Tasquinimod, Paquinimod and SILC
- Out-licensing activities are continuing
- The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
- Product patent for SILC substances granted by the European Patent Office
New share issue
- Rights issue implemented in fourth quarter generating proceeds of SEK 53.7 M for the company after issue expenses
Financial summary
| SEK M | Oct - Dec | Jan - Dec | ||
| 2016 | 2015 | 2016 | 2015 | |
| Net sales | 7.1 | 5.0 | 19.0 | 16.3 |
| Operating loss | -13.5 | -28.2 | -55.1 | -177.9 |
| Loss for the period | -14.8 | -40.8 | -59.6 | -193.5 |
| Loss per share, before and after dilution (SEK) | -0.16 | -0.45 | -0.65 | -2.13 |
| Cash and cash equivalents | 77.7 | 103.6 | ||
- Operating costs for full-year 2016 reduced by 62% (SEK 120.1 M) compared with 2015
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0) 46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/b7db1773-1b32-4839-8243-826cdfe35a48
